Neurelis
Neurelis®: Helping More People Define Their Neu Normal
- Headquarters
- San Diego, California
- Employees
- 51–200
- Business Model
- B2B
- Website
- neurelis.com
- Total Funding
- $314.0M
- Last Round
- $114.0M Series DJun 2023
- Rounds
- 4
About
Neurelis is a neuroscience-focused pharmaceutical company developing treatments for neurological conditions including epilepsy.
Summary
Neurelis is a Biotech company based in San Diego, United States. It has raised $314.0M in total across 4 rounds, most recently a $114.0M Series D round in Jun 2023. Investors include HBM Healthcare Investments, OrbiMed and LYZZ Capital.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2023
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...